Group 1 - The core point of the article highlights that Jinxin Reproductive Medicine (01951) experienced a 5.03% decline in stock price, trading at 3.21 HKD per share with a transaction volume of 216 million HKD as of 14:40 on August 20 [1] - Jinxin Reproductive Medicine is a leading assisted reproductive service provider in China and the US, operating multiple hospitals and medical centers, primarily offering assisted reproductive services and related treatments [1] - According to a Frost & Sullivan report, in 2018, the company ranked third in China's assisted reproductive services market, conducting 20,958 in vitro fertilization cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned assisted reproductive service providers [1] Group 2 - As of the 2024 annual report, Jinxin Reproductive Medicine reported total revenue of 2.812 billion HKD and a net profit of 283 million HKD [2] - The company is set to disclose its interim report for the fiscal year 2025 on August 25 [3]
锦欣生殖(01951)下跌5.03%，报3.21元/股